{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=38", "query": { "intervention": "lenalidomide", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 703, "total_pages": 71, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lenalidomide&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T15:45:11.586Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03729804", "title": "Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2019-05-07", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729804" }, { "nct_id": "NCT01241734", "title": "Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Revlimid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-10", "completion_date": "2015-09-22", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Durham, North Carolina", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241734" }, { "nct_id": "NCT01718899", "title": "Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "PVX-410", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "OncoPep, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 22, "start_date": "2012-11", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-28", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Niles, Illinois • Boston, Massachusetts + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Niles", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01718899" }, { "nct_id": "NCT02075021", "title": "Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-03", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02075021" }, { "nct_id": "NCT04978584", "title": "Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2022-03-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978584" }, { "nct_id": "NCT01207921", "title": "Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2011-04-28", "completion_date": "2021-03-05", "has_results": false, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 3, "location_summary": "St Louis, Missouri • Winston-Salem, North Carolina • Columbus, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207921" }, { "nct_id": "NCT02655458", "title": "Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous PBMC reconstitution", "type": "OTHER" }, { "name": "ASCT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hearn Jay Cho", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-01", "completion_date": "2017-07-13", "has_results": false, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655458" }, { "nct_id": "NCT00890552", "title": "A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia", "Amyloidosis" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-03-22", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890552" }, { "nct_id": "NCT00628238", "title": "Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "CLL", "Untreated", "Front-line", "First-Line", "Initial Therapy" ], "interventions": [ { "name": "Lenalidomide and Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chronic Lymphocytic Leukemia Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 80, "start_date": "2008-02", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2010-09-10", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 5, "location_summary": "La Jolla, California • Boston, Massachusetts • New Hyde Park, New York + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00628238" }, { "nct_id": "NCT00670358", "title": "Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 138, "start_date": "2008-08-25", "completion_date": "2024-10-04", "has_results": true, "last_update_posted_date": "2025-01-10", "last_synced_at": "2026-10-30T15:45:11.586Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00670358" } ] }